0.38
-0.0325(-7.80%)
Currency In USD
| Previous Close | 0.42 |
| Open | 0.4 |
| Day High | 0.41 |
| Day Low | 0.38 |
| 52-Week High | 1.65 |
| 52-Week Low | 0.29 |
| Volume | 801,282 |
| Average Volume | 4.41M |
| Market Cap | 29.85M |
| PE | -0.94 |
| EPS | -0.41 |
| Moving Average 50 Days | 0.73 |
| Moving Average 200 Days | 0.91 |
| Change | -0.03 |
If you invested $1000 in Clearside Biomedical, Inc. (CLSD) since IPO date, it would be worth $52.98 as of August 02, 2025 at a share price of $0.384. Whereas If you bought $1000 worth of Clearside Biomedical, Inc. (CLSD) shares 5 years ago, it would be worth $219.49 as of August 02, 2025 at a share price of $0.384.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
GlobeNewswire Inc.
Jul 23, 2025 11:05 AM GMT
- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLO
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
GlobeNewswire Inc.
Jul 17, 2025 11:05 AM GMT
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
GlobeNewswire Inc.
Jun 17, 2025 11:05 AM GMT
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase Inhibitor - ALPHARETTA, Ga., June 17, 2025 (GLOBE